

Supplementary Material 45 Cost effectiveness scenario analysis – multi-level regression analysis of within-trial costs and QALYs

	Costs	QALYs	ICER	Incremental net health benefit (95% CI)		
	(95% CI)	(95% CI)		k=£15,000	k=£20,000	k=£30,000
	[P(most costly)]	[P(most effective)]		[Probability of being cost-effective]		
Control	£655.92 (479.58, 820.12) [0.043]	0.84332 (0.82177, 0.86587) [0.286]		- - [0.49]	- - [0.444]	- - [0.386]
SWAL only	£733.89 (599.94, 883.22) [0.219]	0.84628 (0.82471, 0.86887) [0.424]	£26,344.84	-0.002 (-0.029, 0.027) [0.365]	-0.001 (-0.026, 0.026) [0.376]	0 (-0.023, 0.026) [0.402]
SWAL plus desk	£803.55 (666.95, 943.34) [0.738]	0.84159 (0.82128, 0.86114) [0.29]	Dominated	-0.009 (-0.041, 0.024) [0.145]	-0.008 (-0.039, 0.024) [0.18]	-0.007 (-0.036, 0.024) [0.212]